Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma

Cytotherapy

Volumn 8, Issue 2, 2006, Pages 141-148

  Wu, J Y ^a   Ernstoff, M S ^a   Hill, J M ^a   Cole, B ^a   Meehan, Kenneth R ^a  

^a NORRIS COTTON CANCER CENTER   (United States)

Author keywords

Effector cells; Ex vivo expansion; Immunotherapy; Myeloma; NKG2D

Indexed keywords

CD56 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; OKT 3; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER PATIENT; CELL MEDIATED LYMPHOLYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; CYTOLYSIS; DRUG RECEPTOR BINDING; EFFECTOR CELL; EX VIVO STUDY; HUMAN; HUMAN CELL; LYMPHOCYTOTOXICITY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MYELOMA; MYELOMA CELL; NATURAL KILLER T CELL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; STEM CELL MOBILIZATION; TUMOR RESISTANCE;

EID: 33646410177     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240600620218     Document Type: Article

References (30)

1. Jemal, A and Murray, T and Samuels, A and et al (2003) Cancer statistics, 2003 CA Cancer J Clin, 53, pp. 5-26.
2. Child, J and Morgan, G and Davies, F. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Eng J Med, 348, pp. 1875-83.
3. Attal, M. and Harousseau, JL and Stoppa, AM and et al. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myelome N Engl J Med, 335, pp. 91-7.
4. Tricot, G and Vesole, DH and Jagannath, S and et al. (1996) Graft-versus-myeloma effect: Proof of principle Blood, 87, pp. 1196-8.
5. Reynolds, C and Ratanatharathorn, V and Adams, P and et al. (2001) Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma Bone Marrow Transplant, 27, pp. 801-7.
6. Hayashi, TT and Hideshima, T and Anderson, K and et al. (2003) Novel therapies for multiple myeloma Br J Haematol, 120, pp. 10-7.
7. + T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation Clin Cancer Res, 5, pp. 461-9.
8. White, HD and Musey, LK and Andrews, MM and et al. (2001) Human immunodeficiency virus-specific and CD3-redirected cytotoxic T lymphocyte activity in the human female reproductive tract: Lack of correlation between mucosa and peripheral blood J Infect Dis, 183, pp. 977 - 83.
9. Dudley, ME. and Wunderlich, JR and Robbins, PF and et al. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science, 298, pp. 850-4.
10. Dudley, ME and Wunderlich, JR and Yang, CJ and et al. (2001) Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma J Immunother, 24, pp. 363-73.
11. Hu, HM and Poehlein, CH and Urba, W and et al. (2002) Development of antitumor immune responses in reconstituted lymphopenic hosts Cancer Res, 62, pp. 3914-9.
12. Porrata, LF and Gertz, MA and Inwards, DJ and et al. (2001) Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma Blood, 98, pp. 579-85.
13. Powles, R and Singhal, S and Treleaven, J and et al. (1998) Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation Blood, 91, pp. 3481-6.
14. Pavletic, ZS and Joshi, SS and Pirruccello, SJ and et al. (1998) Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies Bone Marrow Transplant, 21, pp. 33-41.
15. Szabolcsa, P and Parka, KD and Martia, L and et al. (2004) The impact of immune reconstitution in the early post grafting period on the development of opportunistic infections after unrelated cord blood transplantation. A multivariate analysis of host, graft, and day +50 immune profile Biol Blood Marrow Transplant, 10, pp. 24.
16. Meehan, KR and Slack, R and Gehan, E and et al. (2001) Ex vivo cytokine activation of peripheral blood stem cells: Potential role for adoptive cellular immunotherapy J Hematother Stem Cell Res, 10, pp. 283-90.
17. White, HD and Crassi, KM and Givan, AL and et al. (1997) CD3+ CD8+ CTL activity within the human female reproductive tract: Influence of stage of the menstrual cycle and menopause J Immunol, 158, pp. 3017-27.
18. + T cells Blood, 103, pp. 3065-72.
19. - natural killer T cells specific for MUC1 mucin Cancer Res, 64, pp. 1171-80.
20. Gilfillan, S and Ho, EL and Cella, M and et al. (2002) NKG2D recruits two distinct adapters to trigger NK cell activation and co stimulation Nat Immunol, 3, pp. 1150-5.
21. Vivier, EE and Tomasello and Paul, P. (2002) Lymphocyte activation via NKG2D: Towards a new paradigm in immune recognition? Curr Opin Immunol, 14, pp. 306-11.
22. Seaman, WE. (2000) Natural killer cells and natural killer T cells Arthritis Rheum, 43, pp. 1204-17.
23. Moretta, LR and Biassoni, R and Bottino, C and et al. (2000) Human NK-cell receptors Immunol Today, 21, pp. 420-2.
24. Watzl, C. (2003) The NKG2D receptor and its ligands-recognition beyond the 'missing self'? Microbes Infect, 5, pp. 31-7.
25. Wen, YJ and Min, R and Tricot, G and et al. (2002) Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: Promising effector cells for immunotherapy Blood, 99, pp. 3280-5.
26. + T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection Nat Med, 8, pp. 47-53.
27. + -selected hematopoietic cell transplantation Blood, 102, pp. 2004-13.
28. + T cells after high-dose chemotherapy for metastatic breast cancer J Clin Oncol, 20 58-64
29. Rapoport, AP and Levine, BL and Badros, A and et al. (2004) Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells Bone Marrow Transplant, 33, pp. 53-60.
30. Yi, Q and Desikan, R and Barlogie, B and et al. (2002) Optimizing dendritic cell-based immunotherapy in multiple myeloma Br J Haematol, 117, pp. 297-305.